Related references
Note: Only part of the references are listed.CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Monique B. Nilsson et al.
CANCER CELL (2023)
RHOJ controls EMT-associated resistance to chemotherapy
Maud Debaugnies et al.
NATURE (2023)
Immunotherapies for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Anna Adam-Artigues et al.
SCIENCE ADVANCES (2022)
Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma
Beiyuan Hu et al.
CANCER RESEARCH (2022)
AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization
Tugce Batur et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors
Viola Hedrich et al.
CANCERS (2021)
The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications
Martha Wium et al.
CANCERS (2021)
Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer
Fatema Tuz Zahra et al.
CANCERS (2021)
Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor
Aldo Prawira et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy
Masashi Mikubo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
EGFR activation limits the response of liver cancer to lenvatinib
Haojie Jin et al.
NATURE (2021)
Experience with regorafenib in the treatment of hepatocellular carcinoma
Alessandro Granito et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma
Carmen Oi Ning Leung et al.
HEPATOLOGY (2020)
Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review
Thibaut D'Izarny-Gargas et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma
Haijing Deng et al.
LIVER CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma
Martin Golkowski et al.
CELL SYSTEMS (2020)
Molecular Bases of Drug Resistance in Hepatocellular Carcinoma
Jose J. G. Marin et al.
CANCERS (2020)
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
David J. Pinato et al.
BRITISH JOURNAL OF CANCER (2019)
Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway
Jichuang Wang et al.
CANCER LETTERS (2019)
KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program
Yanmin Xu et al.
CANCER LETTERS (2019)
A Pharmacogenomic Landscape in Human Liver Cancers
Zhixin Qiu et al.
CANCER CELL (2019)
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer
Anushka Dongre et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
Wenliang Tan et al.
EBIOMEDICINE (2019)
Dynamics of CRISPR/Cas9-mediated genomic editing of the AXL locus in hepatocellular carcinoma cells
Irene Scharf et al.
ONCOLOGY LETTERS (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
Marie-Anne Goyette et al.
CELL REPORTS (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
Victoria Tovar et al.
GUT (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Accurate Determination of Soluble Axl by Enzyme-Linked Immunosorbent Assay
Mirko Dengler et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2016)
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling
P-F Zhang et al.
CELL DEATH & DISEASE (2016)
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A. Miller et al.
CANCER DISCOVERY (2016)
Axl Activates Autocrine Transforming Growth Factor-β Signaling in Hepatocellular Carcinoma
Patrick Reichl et al.
HEPATOLOGY (2015)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catherine Wilson et al.
CANCER RESEARCH (2014)
An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
Mihalis S. Kariolis et al.
NATURE CHEMICAL BIOLOGY (2014)
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Erinn B. Rankin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
La enhances IRES-mediated translation of laminin B1 during malignant epithelial to mesenchymal transition
Michaela Petz et al.
NUCLEIC ACIDS RESEARCH (2012)
A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression
Franziska van Zijl et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy
Agda K. Lucio-Eterovic et al.
CLINICAL CANCER RESEARCH (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)